ABIVAX Société Anonyme (AAVXF)
| Market Cap | 7.59B +2.8% |
| Revenue (ttm) | 5.33M -39.0% |
| Net Income | -458.38M |
| EPS | -5.81 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100 |
| Open | 84.80 |
| Previous Close | 84.80 |
| Day's Range | 84.80 - 84.80 |
| 52-Week Range | 71.26 - 139.00 |
| Beta | -0.34 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Dec 14, 2026 |
About ABIVAX Société Anonyme
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France. [Read more]
Financial Performance
In 2025, ABIVAX Société Anonyme's revenue was 4.57 million, a decrease of -63.22% compared to the previous year's 12.43 million. Losses were -336.10 million, 90.7% more than in 2024.
Financial numbers in EUR Financial StatementsNews
Abivax to Participate in Upcoming Fall Investor Conferences
Abivax to Participate in Upcoming Fall Investor Conferences PARIS, France – November 2, 2026 – 10:05 PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”)...
Abivax price target lowered to $118 from $140 at Wedbush
Wedbush lowered the firm’s price target on Abivax (ABVX) to $118 from $140 and keeps a Neutral rating on the shares. The firm notes the company reported Q2/first half of…
Abivax price target lowered to $151 from $155 at Truist
Truist lowered the firm’s price target on Abivax (ABVX) to $151 from $155 and keeps a Buy rating on the shares. The firm is updating its model while noting that…
Abivax appoints Chris Rabbat as Chief Medical Officer
Fabio Cataldi, M.D., Chief Medical Officer, will be leaving Abivax (ABVX) in Q4. Chris Rabbat, Ph.D., who has led Global Medical Affairs since 2023, will succeed Cataldi as Chief Medical…
Abivax Presents Business Updates and First Half 2026 Financial Results
Abivax Presents Business Updates and First Half 2026 Financial Results Chris Rabbat to succeed Fabio Cataldi as Chief Medical Officer; Tim Kelly appointed Chief Technical Officer to advance commercia...
ABIVAX Société Anonyme Earnings release: Q2 2026
ABIVAX Société Anonyme released its Q2 2026 earnings on September 21, 2026, summarizing the period's financial results.
ABIVAX Société Anonyme Quarterly report: Q2 2026
ABIVAX Société Anonyme has published its Q2 2026 quarterly earnings report on September 21, 2026.
Will Abivax Stock (ABVX) Rise or Fall After Q2 Earnings?
Abivax ($ABVX) stock was down 2.43% on Friday ahead of the French pharmaceutical company’s upcoming earnings report. The company is set to release its Q2 2026 earnings during market hours…
Abivax initiated with a Buy at Goldman Sachs
Goldman Sachs initiated coverage of Abivax (ABVX) with a Buy rating and $155 price target Key pipeline asset obefazimod is “uniquely positioned” and differentiated in a competitive market, offering bi...
Abivax announces positive pre-NDA interaction with FDA for obefazimod in UC
Abivax (ABVX) announced the successful completion of its positive pre-New Drug Application interaction with the U.S. Food and Drug Administration for obefazimod for the treatment of adults with modera...
Abivax price target raised to $180 from $132 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Abivax (ABVX) to $180 from $132 and keeps an Overweight rating on the shares. Since the topline maintenance readout from ABTECT and…
Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC
Abivax's latest funding round allows the biotech to move toward a U.S. launch of its bowel disease drug without backing from Big Pharma, its CEO told CNBC on Friday. The French biotech has been under ...
ABIVAX Société Anonyme Slides: Corporate presentation
ABIVAX Société Anonyme has posted slides in relation to its latest quarterly earnings report, which was published on July 10, 2026.
Abivax price target raised to $175 from $165 at Piper Sandler
Piper Sandler raised the firm’s price target on Abivax (ABVX) to $175 from $165 and keeps an Overweight rating on the shares. The firm is raising its ulcerative colitis obefazimod…
Abivax: Wall Street Catches Up to the Data
Shares of Abivax NASDAQ: ABVX were up more than 40% in the month ending July 6, after the company announced positive results from its late-stage (Phase 3) trial of its lead candidate, Obefazimod, whic...
Abivax Announces Closing of $920 Million Public Offering
Abivax Announces Closing of $920 Million Public Offering PARIS, France, July 6, 2026 –10:05 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a cl...
Abivax price target raised to $155 from $135 at Truist
Truist raised the firm’s price target on Abivax (ABVX) to $155 from $135 and keeps a Buy rating on the shares. ollowing maintenance Part 2 data, discussions with Abivax management…
Abivax Shares Continue Climbing After Biotech Firm Moves to Bolster Balance Sheet
Shares rose 5% after the biotech moved to bolster its balance sheet through an upsized stock offering, signaling investor appetite in the wake of positive clinical-trial data.
Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)
Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)
Abivax nears $11 billion valuation after fundraising eases M&A pressure
Abivax SA raised $800 million in an expanded share sale on Wednesday after strong investor demand, valuing the French biotechnology company at nearly $11 billion and easing pressure to pursue a near...
Correction: Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares
Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares
Abivax announces trading resumption of its ordinary shares on Euronext Paris
Abivax announces trading resumption of its ordinary shares on Euronext Paris PARIS, France, July 1, 2026 – 02:50 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”)...
Abivax Announces Pricing of Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares
Abivax Announces Pricing of Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris PARIS, France, July 1, 2026 – 07:30 a.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Compa...
Abivax announces $600M ADS offering
Abivax (ABVX) SA announced the launch of an underwritten public offering of approximately $600M of its American Depositary Shares, or ADSs, each representing one ordinary share of Abivax. All ADSs…